Last reviewed · How we verify
Ketalar
At a glance
| Generic name | Ketalar |
|---|---|
| Also known as | Ketamine, Ketanest, Ketaset, Calipsol, Kalipsol |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Neurobiology of Suicide (PHASE2)
- Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus (PHASE2)
- Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery (PHASE1)
- Intraoperative Ketamine for Chronic Postoperative Pain After Open-Heart Surgery (NA)
- Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts (PHASE4)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketalar CI brief — competitive landscape report
- Ketalar updates RSS · CI watch RSS
- Ain Shams University portfolio CI